Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
11 "Yoon Ho Ko"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Lung and Thoracic cancer
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
Ki Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, Yun-Gyoo Lee, Youngjoo Lee, Jong-Seok Lee, Joo-Hang Kim, Young Joo Min, Gyeong-Won Lee, Sung Sook Lee, Kyung-Hee Lee, Yoon Ho Ko, Byoung Yong Shim, Sang-We Kim, Sang Won Shin, Jin-Hyuk Choi, Dong-Wan Kim, Eun Kyung Cho, Keon Uk Park, Jin-Soo Kim, Sang Hoon Chun, Jangyoung Wang, SeokYoung Choi, Jin Hyoung Kang
Cancer Res Treat. 2024;56(1):48-60.   Published online June 27, 2023
DOI: https://doi.org/10.4143/crt.2023.453
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This subgroup analysis of the Korean subset of patients in the phase 3 LASER301 trial evaluated the efficacy and safety of lazertinib versus gefitinib as first-line therapy for epidermal growth factor receptor mutated (EGFRm) non–small cell lung cancer (NSCLC).
Materials and Methods
Patients with locally advanced or metastatic EGFRm NSCLC were randomized 1:1 to lazertinib (240 mg/day) or gefitinib (250 mg/day). The primary endpoint was investigator-assessed progression-free survival (PFS).
Results
In total, 172 Korean patients were enrolled (lazertinib, n=87; gefitinib, n=85). Baseline characteristics were balanced between the treatment groups. One-third of patients had brain metastases (BM) at baseline. Median PFS was 20.8 months (95% confidence interval [CI], 16.7 to 26.1) for lazertinib and 9.6 months (95% CI, 8.2 to 12.3) for gefitinib (hazard ratio [HR], 0.41; 95% CI, 0.28 to 0.60). This was supported by PFS analysis based on blinded independent central review. Significant PFS benefit with lazertinib was consistently observed across predefined subgroups, including patients with BM (HR, 0.28; 95% CI, 0.15 to 0.53) and those with L858R mutations (HR, 0.36; 95% CI, 0.20 to 0.63). Lazertinib safety data were consistent with its previously reported safety profile. Common adverse events (AEs) in both groups included rash, pruritus, and diarrhoea. Numerically fewer severe AEs and severe treatment–related AEs occurred with lazertinib than gefitinib.
Conclusion
Consistent with results for the overall LASER301 population, this analysis showed significant PFS benefit with lazertinib versus gefitinib with comparable safety in Korean patients with untreated EGFRm NSCLC, supporting lazertinib as a new potential treatment option for this patient population.

Citations

Citations to this article as recorded by  
  • First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis
    Jietao Ma, Xiaoxue Pang, Shuling Zhang, Letian Huang, Li Sun, Chengbo Han
    Scientific Reports.2024;[Epub]     CrossRef
  • 6,124 View
  • 578 Download
  • 3 Web of Science
  • 1 Crossref
Close layer
Gastrointestinal cancer
A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10)
Keun-Wook Lee, Dae Young Zang, Min-Hee Ryu, Hye Sook Han, Ki Hyang Kim, Mi-Jung Kim, Sung Ae Koh, Sung Sook Lee, Dong-Hoe Koo, Yoon Ho Ko, Byeong Seok Sohn, Jin Won Kim, Jin Hyun Park, Byung-Ho Nam, In Sil Choi
Cancer Res Treat. 2023;55(4):1250-1260.   Published online May 25, 2023
DOI: https://doi.org/10.4143/crt.2023.333
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study evaluated whether combination therapy is more effective than monotherapy in elderly patients with metastatic or recurrent gastric cancer (MRGC) as first-line chemotherapy.
Materials and Methods
Elderly (≥ 70 years) chemo-naïve patients with MRGC were allocated to receive either combination therapy (group A: 5-fluorouracil [5-FU]/oxaliplatin, capecitabine/oxaliplatin, capecitabine/cisplatin, or S-1/cisplatin) or monotherapy (group B: 5-FU, capecitabine, or S-1). In group A, starting doses were 80% of standard doses, and they could be escalated to 100% at the discretion of the investigator. Primary endpoint was to confirm superior overall survival (OS) of combination therapy vs. monotherapy.
Results
After 111 of the planned 238 patients were randomized, enrollment was terminated due to poor accrual. In the full-analysis population (group A [n=53] and group B [n=51]), median OS of combination therapy vs. monotherapy was 11.5 vs. 7.5 months (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.56 to 1.30; p=0.231). Median progression-free survival (PFS) was 5.6 vs. 3.7 months (HR, 0.53; 95% CI, 0.34 to 0.83; p=0.005). In subgroup analyses, patients aged 70-74 years tended to have superior OS with combination therapy (15.9 vs. 7.2 months, p=0.056). Treatment-related adverse events (TRAEs) occurred more frequently in group A vs. group B. However, among severe TRAEs (≥ grade 3), there were no TRAEs with a frequency difference of > 5%.
Conclusion
Combination therapy was associated with numerically improved OS, although statistically insignificant, and a significant PFS benefit compared with monotherapy. Although combination therapy showed more frequent TRAEs, there was no difference in the frequency of severe TRAEs.

Citations

Citations to this article as recorded by  
  • A prognostic nomogram to predict the cancer-specific survival of patients with initially diagnosed metastatic gastric cancer: a validation study in a Chinese cohort
    Ziming Zhao, Erxun Dai, Bao Jin, Ping Deng, Zulihaer Salehebieke, Bin Han, Rongfan Wu, Zhaowu Yu, Jun Ren
    Clinical and Translational Oncology.2024;[Epub]     CrossRef
  • 3,664 View
  • 299 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy
Jin Won Kim, Se Hyun Kim, Yun-Gyoo Lee, In Gyu Hwang, Jin Young Kim, Su-Jin Koh, Yoon Ho Ko, Seong Hoon Shin, In Sook Woo, Soojung Hong, Tae-Yong Kim, Ji Yeon Baek, Hyun Jung Kim, Hyo Jung Kim, Myung Ah Lee, Jung Hye Kwon, Yong Sang Hong, Hun-Mo Ryoo, Kyung Hee Lee, Jee Hyun Kim
Cancer Res Treat. 2019;51(3):1249-1256.   Published online January 2, 2019
DOI: https://doi.org/10.4143/crt.2018.451
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to prospectively validate the Korean Cancer Study Group Geriatric Score (KG)-7, a novel geriatric screening tool, in older patients with advanced cancer planned to undergo first-line palliative chemotherapy.
Materials and Methods
Participants answered the KG-7 questionnaire before undergoing geriatric assessment (GA) and first-line palliative chemotherapy. The performance of KG-7 was evaluated by calculating the sensitivity (SE), specificity (SP), positive and negative predictive value (PPV and NPV), balanced accuracy (BA), and area under the curve (AUC).
Results
The baseline GA and KG-7 results were collected from 301 patients. The median age was 75 years (range, 70 to 93 years). Abnormal GA was documented in 222 patients (73.8%). Based on the ≤ 5 cut-off value of KG-7 for abnormal GA, abnormal KG-7 score was shown in 200 patients (66.4%). KG-7 showed SE, SP, PPV, NPV, and BA of 75.7%, 59.7%, 84.4%, 46.0%, and 67.7%, respectively; AUC was 0.745 (95% confidence interval, 0.687 to 0.803). Furthermore, patients with higher KG-7 scores showed significantly longer survival (p=0.006).
Conclusion
KG-7 appears to be adequate in identifying patients with abnormal GA prospectively. Hence, KG-7 can be a useful screening tool for Asian countries with limited resources and high patient volume.

Citations

Citations to this article as recorded by  
  • Comparison of two frailty screening tools in older patients with colorectal cancer
    Han Zhao, Xinlin Lu, Senshuang Zheng, Danmei Wei, Lizhong Zhao, Yuan Wang, Geertruida H. de Bock, Wenli Lu
    BMC Geriatrics.2023;[Epub]     CrossRef
  • Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study
    In Gyu Hwang, Minsuk Kwon, Jin Won Kim, Se Hyun Kim, Yun-Gyoo Lee, Jin Young Kim, Su-Jin Koh, Yoon Ho Ko, Seong Hoon Shin, Soojung Hong, Tae-Yong Kim, Sun Young Kim, Hyun Jung Kim, Hyo Jung Kim, Myung Ah Lee, Jung Hye Kwon, Yong Sang Hong, Kyung Hee Lee,
    Cancers.2021; 13(2): 331.     CrossRef
  • A single-arm feasibility study of gradual dose de-escalation of antiemetic dexamethasone for older patients receiving chemotherapy
    Koung Jin Suh, Seonghae Yoon, Jin Won Kim, Seo Hyun Yoon, Ji-Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jee Hyun Kim
    Journal of Geriatric Oncology.2021; 12(6): 922.     CrossRef
  • Predictive Value of Geriatric Oncology Screening and Geriatric Assessment in Older Patients with Solid Cancers: Protocol for a Danish prospective cohort study (PROGNOSIS-G8)
    Helena Møgelbjerg Ditzel, Ann-Kristine Weber Giger, Cecilia Margareta Lund, Henrik Jørn Ditzel, Afsaneh Mohammadnejad, Per Pfeiffer, Jesper Ryg, Trine Lembrecht Jørgensen, Marianne Ewertz
    Journal of Geriatric Oncology.2021; 12(8): 1270.     CrossRef
  • The Globalization of Geriatric Oncology: From Data to Practice
    Ravindran Kanesvaran, Supriya Mohile, Enrique Soto-Perez-de-Celis, Harpreet Singh
    American Society of Clinical Oncology Educational Book.2020; (40): e107.     CrossRef
  • 9,510 View
  • 180 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer
Jin Won Kim, Jong Gwang Kim, Byung Woog Kang, Ik-Joo Chung, Young Seon Hong, Tae-You Kim, Hong Suk Song, Kyung Hee Lee, Dae Young Zang, Yoon Ho Ko, Eun-Kee Song, Jin Ho Baek, Dong‐Hoe Koo, So Yeon Oh, Hana Cho, Keun-Wook Lee
Cancer Res Treat. 2019;51(1):223-239.   Published online October 19, 2018
DOI: https://doi.org/10.4143/crt.2018.073
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to evaluate chemotherapy patterns and changes in quality of life (QOL) during first-line palliative chemotherapy for Korean patients with unresectable or metastatic/recurrent gastric cancer (GC).
Materials and Methods
Thiswas a non-interventional, multi-center, prospective, observational study of 527 patients in Korea. QOL assessments were conducted using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 and QLQ-STO22 every 3 months over a 12-month period during first-line palliative chemotherapy. The specific chemotherapy regimens were selected by individual clinicians.
Results
Most patients (93.2%) received combination chemotherapy (mainly fluoropyrimidine plus platinum) as their first-line palliative chemotherapy. The median progression-free survival and overall survival were 8.2 and 14.8 months, respectively. Overall, “a little” changes (differences of 5-10 points from baseline)were observed in some of the functioning or symptom scales; none of the QOL scales showed either “moderate” or “very much” change (i.e., ≥ 11 point difference from baseline). When examining the best change in each QOL domain from baseline, scales related to some aspects of functioning, global health status/QOL, and most symptoms revealed significant improvements (p < 0.05). Throughout the course of first-line palliative chemotherapy, most patients’ QOL was maintained to a similar degree, regardless of their actual response to chemotherapy.
Conclusion
This observational study provides important information on the chemotherapy patterns and QOL changes in Korean patientswith advanced GC. Overall, first-line palliative chemotherapy was found to maintain QOL, and most parameters showed an improvement compared with the baseline at some point during the course.

Citations

Citations to this article as recorded by  
  • Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer
    Z.A. Wainberg, P.C. Enzinger, S. Qin, K. Yamaguchi, J. Wang, X. Zhou, A. Gnanasakthy, K. Taylor, A. Yusuf, I. Majer, A. Jamotte, Y.-K. Kang
    ESMO Gastrointestinal Oncology.2024; 6: 100095.     CrossRef
  • Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer
    Adán Rodríguez-Gonzalez, Alberto Carmona-Bayonas, Raquel Hernandez San Gil, Patricia Cruz-Castellanos, Mónica Antoñanzas-Basa, David Lorente-Estelles, María Jose Corral, Manuel González-Moya, Oscar Alfredo Castillo-Trujillo, Emilio Esteban, Paula Jiménez-
    Clinical and Translational Oncology.2023; 25(12): 3492.     CrossRef
  • Reminiscence therapy-based care program alleviates anxiety and depression, as well as improves the quality of life in recurrent gastric cancer patients
    Xing Wu, Weiwei Zhang
    Frontiers in Psychology.2023;[Epub]     CrossRef
  • Toxicities and Quality of Life during Cancer Treatment in Advanced Solid Tumors
    Eun Mi Lee, Paula Jiménez-Fonseca, Rocio Galán-Moral, Sara Coca-Membribes, Ana Fernández-Montes, Elena Sorribes, Esmeralda García-Torralba, Laura Puntí-Brun, Mireia Gil-Raga, Juana Cano-Cano, Caterina Calderon
    Current Oncology.2023; 30(10): 9205.     CrossRef
  • Psychosocial functioning in individuals with advanced oesophago-gastric cancer: a mixed methods systematic review
    Cara Ghiglieri, Martin Dempster, Sam Wright, Lisa Graham-Wisener
    BMC Palliative Care.2023;[Epub]     CrossRef
  • Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)
    Keun-Wook Lee, Ik-Joo Chung, Min-Hee Ryu, Young Iee Park, Byung-Ho Nam, Ho-Suk Oh, Kyung Hee Lee, Hye Sook Han, Bong-Gun Seo, Jae-Cheol Jo, Hyo Rak Lee, Jin Won Kim, Sook Ryun Park, Sang Hee Cho, Yoon-Koo Kang
    Gastric Cancer.2021; 24(1): 156.     CrossRef
  • Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial
    Kazumasa Fujitani, Kohei Shitara, Atsuo Takashima, Keisuke Koeda, Hiroki Hara, Norisuke Nakayama, Shuichi Hironaka, Kazuhiro Nishikawa, Yutaka Kimura, Kenji Amagai, Hisashi Hosaka, Yoshito Komatsu, Ken Shimada, Ryohei Kawabata, Hideki Ohdan, Yasuhiro Kode
    Gastric Cancer.2021; 24(2): 467.     CrossRef
  • Quality-of-Life Assessment in Patients Receiving Palliative Chemotherapy: Call for Action
    Maheswari Senthil
    Annals of Surgical Oncology.2021; 28(1): 7.     CrossRef
  • Impact of gastric cancer treatment on quality of life of patients
    Kerstin Schütte, Christian Schulz, Kristina Middelberg-Bisping
    Best Practice & Research Clinical Gastroenterology.2021; 50-51: 101727.     CrossRef
  • Influencing Factors and Effects of Treatment on Quality of Life in Patients With Gastric Cancer—A Systematic Review
    Sophia Kristina Rupp, Andreas Stengel
    Frontiers in Psychiatry.2021;[Epub]     CrossRef
  • Chronological changes in quality of life and body composition after gastrectomy for locally advanced gastric cancer
    Ki Bum Park, Ji Yeon Park, Seung Soo Lee, Ho Young Chung, Oh Kyoung Kwon
    Annals of Surgical Treatment and Research.2020; 98(5): 262.     CrossRef
  • Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome
    Hannah Christina Puhr, Eleonore Pablik, Anna Sophie Berghoff, Gerd Jomrich, Sebastian Friedrich Schoppmann, Matthias Preusser, Aysegül Ilhan-Mutlu
    ESMO Open.2020; 5(2): e000623.     CrossRef
  • 11,451 View
  • 235 Download
  • 12 Web of Science
  • 12 Crossref
Close layer
Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma
Sun Min Lim, Sang Hee Cho, In Gyu Hwang, Jae Woo Choi, Hyun Chang, Myung-Ju Ahn, Keon Uk Park, Ji-Won Kim, Yoon Ho Ko, Hee Kyung Ahn, Byoung Chul Cho, Byung-Ho Nam, Sang Hoon Chun, Ji Hyung Hong, Jung Hye Kwon, Jong Gwon Choi, Eun Joo Kang, Tak Yun, Keun-Wook Lee, Joo-Hang Kim, Jin Soo Kim, Hyun Woo Lee, Min Kyoung Kim, Dongmin Jung, Ji Eun Kim, Bhumsuk Keam, Hwan Jung Yun, Sangwoo Kim, Hye Ryun Kim
Cancer Res Treat. 2019;51(1):300-312.   Published online May 9, 2018
DOI: https://doi.org/10.4143/crt.2018.012
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Head and neck squamous cell carcinoma (HNSCC) is a deadly disease in which precision medicine needs to be incorporated. We aimed to implement next-generation sequencing (NGS) in determining actionable targets to guide appropriate molecular targeted therapy in HNSCC patients.
Materials and Methods
Ninety-three tumors and matched blood samples underwent targeted sequencing of 244 genes using the Illumina HiSeq 2500 platform with an average depth of coverage of greater than 1,000×. Clinicopathological data from patients were obtained from 17 centers in Korea, and were analyzed in correlation with NGS data.
Results
Ninety-two of the 93 tumors were amenable to data analysis. TP53 was the most common mutation, occurring in 47 (51%) patients, followed by CDKN2A (n=23, 25%), CCND1 (n=22, 24%), and PIK3CA (n=19, 21%). The total mutational burden was similar between human papillomavirus (HPV)–negative vs. positive tumors, although TP53, CDKN2A and CCND1 gene alterations occurred more frequently in HPV-negative tumors. HPV-positive tumors were significantly associated with immune signature-related genes compared to HPV-negative tumors. Mutations of NOTCH1 (p=0.027), CDKN2A (p < 0.001), and TP53 (p=0.038) were significantly associated with poorer overall survival. FAT1 mutations were highly enriched in cisplatin responders, and potentially targetable alterations such as PIK3CA E545K and CDKN2A R58X were noted in 14 patients (15%).
Conclusion
We found several targetable genetic alterations, and our findings suggest that implementation of precision medicine in HNSCC is feasible. The predictive value of each targetable alteration should be assessed in a future umbrella trial using matched molecular targeted agents.

Citations

Citations to this article as recorded by  
  • Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial
    Bhumsuk Keam, Min Hee Hong, Seong Hoon Shin, Seong Gu Heo, Ji Eun Kim, Hee Kyung Ahn, Yun-Gyoo Lee, Keon-Uk Park, Tak Yun, Keun-Wook Lee, Sung-Bae Kim, Sang-Cheol Lee, Min Kyoung Kim, Sang Hee Cho, So Yeon Oh, Sang-Gon Park, Shinwon Hwang, Byung-Ho Nam, S
    Journal of Clinical Oncology.2024; 42(5): 507.     CrossRef
  • A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial
    Kyoo Hyun Kim, Sun Min Lim, Hee Kyung Ahn, Yun-Gyoo Lee, Keun-Wook Lee, Myung-Ju Ahn, Bhumsuk Keam, Hye Ryun Kim, Hyun Woo Lee, Ho Jung An, Jin-Soo Kim
    Cancer Research and Treatment.2024; 56(1): 37.     CrossRef
  • Extracellular vesicles as tools and targets in therapy for diseases
    Mudasir A. Kumar, Sadaf K. Baba, Hana Q. Sadida, Sara Al. Marzooqi, Jayakumar Jerobin, Faisal H. Altemani, Naseh Algehainy, Mohammad A. Alanazi, Abdul-Badi Abou-Samra, Rakesh Kumar, Ammira S. Al-Shabeeb Akil, Muzafar A. Macha, Rashid Mir, Ajaz A. Bhat
    Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
  • Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
    Dong Hyun Kim, Seung Taek Lim, Hye Ryun Kim, Eun Joo Kang, Hee Kyung Ahn, Yun-Gyoo Lee, Der Sheng Sun, Jung Hye Kwon, Sang-Cheol Lee, Hyun Woo Lee, Min Kyoung Kim, Bhumsuk Keam, Keon-Uk Park, Seong-Hoon Shin, Hwan Jung Yun
    Oral Oncology.2024; 151: 106739.     CrossRef
  • Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature
    Lei Liu, Qiang Liu
    Scientific Reports.2024;[Epub]     CrossRef
  • The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer
    Antea Krsek, Lara Baticic, Tamara Braut, Vlatka Sotosek
    Biomolecules.2024; 14(8): 925.     CrossRef
  • Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy
    Kamal S. Saini, Sasikala Somara, Heidi C. Ko, Purva Thatai, Angela Quintana, Zachary D. Wallen, Michelle F. Green, Ravi Mehrotra, Sandra McGuigan, Lingjuan Pang, Soma Das, Kavita Yadav, Dobrica Neric, Luca Cantini, Chinmayee Joshi, Kazuya Iwamoto, Sudha D
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Massive parallel sequencing of head and neck conventional squamous cell carcinomas: A comprehensive review
    Alfons Nadal, Antonio Cardesa, Abbas Agaimy, Alhadi Almangush, Alessandro Franchi, Henrik Hellquist, Ilmo Leivo, Nina Zidar, Alfio Ferlito
    Virchows Archiv.2024; 485(6): 965.     CrossRef
  • FAT1 expression in T-cell acute lymphoblastic leukemia (T-ALL) modulates proliferation and WNT signaling
    Sven Liebig, Martin Neumann, Patricia Silva, Jutta Ortiz-Tanchez, Veronika Schulze, Konstandina Isaakidis, Cornelia Schlee, Michael P. Schroeder, Thomas Beder, Luc G. T. Morris, Timothy A. Chan, Lorenz Bastian, Thomas Burmeister, Stefan Schwartz, Nicola G
    Scientific Reports.2023;[Epub]     CrossRef
  • Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors
    Paula Krone, Annabell Wolff, Julia Teichmann, Johanna Maennicke, Julia Henne, Leonie Engster, Inken Salewski, Wendy Bergmann, Christian Junghanss, Claudia Maletzki
    OncoImmunology.2023;[Epub]     CrossRef
  • Genetic Mutations Associated with Inflammatory Response Caused by HPV Integration in Oropharyngeal Squamous Cell Carcinoma
    Mai Atique, Isis Muniz, Fatemeh Farshadi, Michael Hier, Alex Mlynarek, Marco Macarella, Mariana Maschietto, Belinda Nicolau, Moulay A. Alaoui-Jamali, Sabrina Daniela da Silva
    Biomedicines.2023; 12(1): 24.     CrossRef
  • New Treatment Development for Larynx Preservation
    Susumu Okano
    Koutou (THE LARYNX JAPAN).2023; 35(2): 98.     CrossRef
  • Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer
    Roberto N. Solis, Dustin A. Silverman, Andrew C. Birkeland
    Current Treatment Options in Oncology.2022; 23(2): 254.     CrossRef
  • EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma
    Shengjin Dou, Lin Zhang, Chong Wang, Yanli Yao, Wen Jiang, Lulu Ye, Jiang Li, Sicheng Wu, Debin Sun, Xiaoli Gong, Rongrong Li, Guopei Zhu
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Diagnostics of HNSCC Patients: An Analysis of Cell Lines and Patient-Derived Xenograft Models for Personalized Therapeutical Medicine
    Ramona Gabriela Ursu, Ionut Luchian, Costin Damian, Elena Porumb-Andrese, Nicolae Ghetu, Roxana Gabriela Cobzaru, Catalina Lunca, Carmen Ripa, Diana Costin, Igor Jelihovschi, Florin Dumitru Petrariu, Luminita Smaranda Iancu
    Diagnostics.2022; 12(5): 1071.     CrossRef
  • Unraveling most abundant mutational signatures in head and neck cancer
    Michaela Plath, Johanna Gass, Mario Hlevnjak, Qiaoli Li, Bohai Feng, Xavier Pastor Hostench, Matthias Bieg, Lea Schroeder, Dana Holzinger, Marc Zapatka, Kolja Freier, Wilko Weichert, Jochen Hess, Karim Zaoui
    International Journal of Cancer.2021; 148(1): 115.     CrossRef
  • Worldwide prevalence of PI3K-AKT-mTOR pathway mutations in head and neck cancer: A systematic review and meta-analysis
    Adriana Castelo de Moura, Daniele Xavier Assad, Juliana Amorim dos Santos, Isabela Porto de Toledo, Gustavo Barcelos Barra, Rogerio Moraes Castilho, Cristiane Helena Squarize, Eliete Neves Silva Guerra
    Critical Reviews in Oncology/Hematology.2021; 160: 103284.     CrossRef
  • Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives
    Stijn J. De Keukeleire, Tijl Vermassen, Elien Hilgert, David Creytens, Liesbeth Ferdinande, Sylvie Rottey
    Cancers.2021; 13(7): 1714.     CrossRef
  • Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma
    Bhumsuk Keam, Jin-Young Park, Jin-Pyo Kim, Gun-Do Kim, Yun-Suk Yu, Sang-Hee Cho, Sangwoo Kim, Hee-Kyung Ahn, Sang-Hoon Chun, Jung-Hye Kwon, Tak Yun, Ji-Won Kim, Ji-Eun Kim, Myung-Ju Ahn, Joo-Hang Kim, Hwan-Jung Yun
    Processes.2021; 9(5): 792.     CrossRef
  • Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
    Teresa Magnes, Sandro Wagner, Dominik Kiem, Lukas Weiss, Gabriel Rinnerthaler, Richard Greil, Thomas Melchardt
    International Journal of Molecular Sciences.2021; 22(9): 4981.     CrossRef
  • A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim
    Cancer Medicine.2021; 10(20): 7012.     CrossRef
  • Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma
    Nan Jin, Bhumsuk Keam, Janice Cho, Michelle J. Lee, Hye Ryun Kim, Hayarpi Torosyan, Natalia Jura, Patrick K.S. Ng, Gordon B. Mills, Hua Li, Yan Zeng, Zohar Barbash, Gabi Tarcic, Hyunseok Kang, Julie E. Bauman, Mi-Ok Kim, Nathan K. VanLandingham, Danielle
    Journal of Clinical Investigation.2021;[Epub]     CrossRef
  • Understanding the Pattern of Oropharyngeal Cancers from North-East Romanian Patients
    Ramona Ursu, Simona Giusca, Irene Spiridon, Bianca Manole, Mihai Danciu, Victor Costan, Dragos Palade, Nicolae Ghetu, Paula Toader, Mădălina Vlad, Costin Damian, Elena Porumb-Andrese, Ionut Luchian, Luminița Iancu
    Applied Sciences.2021; 11(24): 12079.     CrossRef
  • Immunologic and immunogenomic aspects of tumor progression
    Andrea Ladányi, József Tímár
    Seminars in Cancer Biology.2020; 60: 249.     CrossRef
  • Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer
    Thomas C. Westbrook, Ian S. Hagemann, Jessica Ley, Kevin Chen, Kevin Palka, Jingxia Liu, Ling Chen, Peter Oppelt, Douglas Adkins
    Medical Oncology.2020;[Epub]     CrossRef
  • Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation
    Martijn van der Heijden, Paul B. M. Essers, Monique C. de Jong, Reinout H. de Roest, Sebastian Sanduleanu, Caroline V. M. Verhagen, Olga Hamming-Vrieze, Frank Hoebers, Philippe Lambin, Harry Bartelink, C. René Leemans, Marcel Verheij, Ruud H. Brakenhoff,
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
    Min Hwan Kim, Jae-Hwan Kim, Ji Min Lee, Jae Woo Choi, Dongmin Jung, Hojin Cho, Hyundeok Kang, Min Hee Hong, Su Jin Heo, Se Heon Kim, Eun Chang Choi, Da Hee Kim, Young Min Park, Sangwoo Kim, Sun Och Yoon, Yoon Woo Koh, Byoung Chul Cho, Hye Ryun Kim
    British Journal of Cancer.2020; 122(11): 1649.     CrossRef
  • Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
    Han Na Kang, Jae-Hwan Kim, A-Young Park, Jae Woo Choi, Sun Min Lim, Jinna Kim, Eun Joo Shin, Min Hee Hong, Kyoung-Ho Pyo, Mi Ran Yun, Dong Hwi Kim, Hanna Lee, Sun Och Yoon, Da Hee Kim, Young Min Park, Hyung Kwon Byeon, Inkyung Jung, Soonmyung Paik, Yoon W
    BMC Cancer.2020;[Epub]     CrossRef
  • Impact of genetic variants in clinical outcome of a cohort of patients with oropharyngeal squamous cell carcinoma
    Ana Carolina de Carvalho, Sandra Perdomo, Wellington dos Santos, Gabriela Carvalho Fernandes, Lais Machado de Jesus, Raiany Santos Carvalho, Cristovam Scapulatempo-Neto, Gisele Caravina de Almeida, Bruna Pereira Sorroche, Lidia Maria Rebolho Batista Arant
    Scientific Reports.2020;[Epub]     CrossRef
  • Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma
    Hyun Chang, Yun-Gyoo Lee, Yoon Ho Ko, Jang Ho Cho, Jong-Kwon Choi, Keon Uk Park, Eun Joo Kang, Keun-Wook Lee, Sun Min Lim, Jin-Soo Kim, Hyun Woo Lee, Min Kyoung Kim, In Gyu Hwang, Sangwoo Kim, Byung-Ho Nam, Hye Ryun Kim
    Cancers.2020; 12(7): 1777.     CrossRef
  • Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
    Hye Ryun Kim, Han Na Kang, Mi Ran Yun, Kwon Young Ju, Jae Woo Choi, Dong Min Jung, Kyoung Ho Pyo, Min Hee Hong, Myoung-Ju Ahn, Jong-Mu Sun, Han Sang Kim, Jinna Kim, Jinseon Yoo, Kyu Ryung Kim, Yoon Woo Koh, Se Heon Kim, Eun Chang Choi, Sun Ock Yoon, Hyo S
    British Journal of Cancer.2020; 123(12): 1720.     CrossRef
  • Mutationssignaturen beim Kopf- und Hals-Tumor
    M. Plath, J. Hess, K. Zaoui
    HNO.2020; 68(12): 922.     CrossRef
  • BAMixChecker: an automated checkup tool for matched sample pairs in NGS cohort
    Hein Chun, Sangwoo Kim, Inanc Birol
    Bioinformatics.2019; 35(22): 4806.     CrossRef
  • Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting
    Panagiota Economopoulou, Remco de Bree, Ioannis Kotsantis, Amanda Psyrri
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • A Review of HPV-Related Head and Neck Cancer
    Kazuhiro Kobayashi, Kenji Hisamatsu, Natsuko Suzui, Akira Hara, Hiroyuki Tomita, Tatsuhiko Miyazaki
    Journal of Clinical Medicine.2018; 7(9): 241.     CrossRef
  • 15,279 View
  • 650 Download
  • 35 Web of Science
  • 35 Crossref
Close layer
Case Report
Pseudocirrhosis of Breast Cancer Metastases to the Liver Treated by Chemotherapy
Su Lim Lee, Eun Deok Chang, Sae Jung Na, Jeong Soo Kim, Ho Jung An, Yoon Ho Ko, Hye Sung Won
Cancer Res Treat. 2014;46(1):98-103.   Published online January 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.1.98
AbstractAbstract PDFPubReaderePub
Pseudocirrhosis refers to a condition that shows changes in hepatic contour that mimic cirrhosis radiographically in the absence of the typical histopathological findings of cirrhosis. This condition has been observed in patients with cancer metastatic to the liver, both in those who have undergone prior systemic chemotherapy and those who have not. Pseudocirrhosis may cause difficulty in interpretation of the response to chemotherapy and hepatic decompression and complication of portal hypertension have a negative effect on the prognosis. We report on a case of breast cancer with liver metastases that showed cirrhotic changes during disease progression. Progression of liver metastases was confirmed by F18 fluorodeoxyglucose positron emission tomography/computed tomography (PET-CT). We also performed ultrasound-guided liver biopsy and confirmed tumor infiltration with severe desmoplastic fibrosis. This case suggests the pathogenesis of pseudocirrhosis through histopathological findings and the role of PET-CT in evaluation of the response to chemotherapy in patients with pseudocirrhosis.

Citations

Citations to this article as recorded by  
  • Pseudocirrhosis: A Case Series with Clinical and Radiographic Correlation and Review of the Literature
    Gal Sadlik, Redmond-Craig Anderson, Xiaomeng Lei, Steven Yong Cen, Vinay A. Duddalwar, Tse-Ling Fong
    Digestive Diseases and Sciences.2024; 69(3): 1004.     CrossRef
  • Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study
    Laura A. Huppert, Zak Walker, Moming Li, Mi-Ok Kim, Jennifer Callan, Danielle Brandman, Melanie Majure, Michelle E. Melisko, Hope S. Rugo, Spencer Behr, A. Jo Chien
    Breast Cancer Research and Treatment.2023; 197(1): 137.     CrossRef
  • Imaging in metastatic breast cancer, CT, PET/CT, MRI, WB-DWI, CCA: review and new perspectives
    Dione Lother, Marie Robert, Elliot Elwood, Sam Smith, Nina Tunariu, Stephen R.D. Johnston, Marina Parton, Basrull Bhaludin, Thomas Millard, Kate Downey, Bhupinder Sharma
    Cancer Imaging.2023;[Epub]     CrossRef
  • Pseudocirrhosis Due to Desmoplastic Response to Chemotherapy in Breast Cancer Liver Metastases
    Kazuhide Takata, Ai Mogi, Ryo Yamauchi, Satoshi Shakado, Fumihito Hirai
    Cureus.2022;[Epub]     CrossRef
  • Liver Metastases: Correlation between Imaging Features and Pathomolecular Environments
    Kumi Ozaki, Shohei Higuchi, Hirohiko Kimura, Toshifumi Gabata
    RadioGraphics.2022; 42(7): 1994.     CrossRef
  • Clinical Outcomes of Metastatic Breast Cancer in Patients Having Imaging Liver Pseudocirrhosis with or without Evident Varices
    Wei-Li Ma, Dwan-Ying Chang, Ching-Hung Lin, Kao-Lang Liu, Po-Chin Liang, Huang-Chun Lien, Chan-Chuan Hu, Ling-Yun Huang, Yi-Chun Yeh, Yen-Shen Lu
    The Oncologist.2022; 27(12): 1008.     CrossRef
  • Pseudocirrhosis and portal hypertension in patients with metastatic cancers: a systematic review and meta-analysis
    Rosanna Villani, Francesca Di Cosimo, Moris Sangineto, Antonino Davide Romano, Gaetano Serviddio
    Scientific Reports.2022;[Epub]     CrossRef
  • Pseudocirrhosis in Breast Cancer – Experience From an Academic Cancer Center
    Dharmesh Gopalakrishnan, Ain Shajihan, Andrei S. Purysko, Jame Abraham
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Unveiling the unreal: Comprehensive imaging review of hepatic pseudolesions
    Subramaniyan Ramanathan, Vineetha Raghu, Vivek Virmani, Adnan Sheikh, Mahmoud Al Heidous, SreeHarsha Tirumani
    Clinical Imaging.2021; 80: 439.     CrossRef
  • Pseudocirrhosis after chemotherapy for gastric cancer with diffuse liver metastases: A case report
    Tomohito Shinoda, Toshiyuki Tanahashi, Takuji Sakuratani, Masato Ota, Seito Fujibayashi, Shunya Kiriyama, Keita Matsumoto, Kazunori Yawata, Yoshiyuki Sasaki, Shinji Osada, Makoto Yamada
    Molecular and Clinical Oncology.2021;[Epub]     CrossRef
  • Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis
    Linda Calistri, Vieri Rastrelli, Cosimo Nardi, Davide Maraghelli, Sofia Vidali, Michele Pietragalla, Stefano Colagrande
    World Journal of Gastroenterology.2021; 27(46): 7866.     CrossRef
  • Clinical features of pseudocirrhosis in metastatic breast cancer
    Caspian Oliai, Michael L. Douek, Caelainn Rhoane, Abhishek Bhutada, Phillip S. Ge, Bruce A. Runyon, Xiaoyan Wang, Sara A. Hurvitz
    Breast Cancer Research and Treatment.2019; 177(2): 409.     CrossRef
  • Seudocirrosis en cáncer de mama metastásico
    Alba Hidalgo-Blanco, Maddi Aguirresarobe-Gil de San Vicente, Santi Aresti, Eduardo de Miguel, Jose Luis Cabriada-Nuno
    Gastroenterología y Hepatología.2018; 41(2): 111.     CrossRef
  • Pseudocirrhosis in metastatic breast cancer
    Alba Hidalgo-Blanco, Maddi Aguirresarobe-Gil de San Vicente, Santi Aresti, Eduardo de Miguel, Jose Luis Cabriada-Nuno
    Gastroenterología y Hepatología (English Edition).2018; 41(2): 111.     CrossRef
  • Pseudocirrhosis after chemotherapy in breast cancer, case reports
    Tomoyoshi Aoyagi, Kazuaki Takabe, Tamaki Tamanuki, Hisahiro Matsubara, Hiroshi Matsuzaki
    Breast Cancer.2018; 25(5): 614.     CrossRef
  • Unintended Consequences of Systemic and Ablative Oncologic Therapy in the Abdomen and Pelvis
    Julie C. Birch, Gaurav Khatri, Lori M. Watumull, Yull E. Arriaga, John R. Leyendecker
    RadioGraphics.2018; 38(4): 1158.     CrossRef
  • Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension-Induced Refractory Ascites Due to Metastatic Carcinomatous Liver Disease
    Barbara Geeroms, Gert De Hertogh, Ragna Vanslembrouck, Hans Wildiers, Frederik Nevens, Geert Maleux
    Journal of Vascular and Interventional Radiology.2018; 29(12): 1713.     CrossRef
  • Delineating Extramammary Findings at Breast MR Imaging
    Yiming Gao, Opeyemi Ibidapo, Hildegard K. Toth, Linda Moy
    RadioGraphics.2017; 37(1): 10.     CrossRef
  • Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases
    Kensuke Kumamoto, Shungo Endo, Noriyuki Isohata, Azuma Nirei, Daiki Nemoto, Kenichi Utano, Takuro Saito, Kazutomo Togashi
    Molecular and Clinical Oncology.2017; 6(1): 63.     CrossRef
  • Systemic treatment in breast cancer: a primer for radiologists
    Aya Y. Michaels, Abhishek R. Keraliya, Sree Harsha Tirumani, Atul B. Shinagare, Nikhil H. Ramaiya
    Insights into Imaging.2016; 7(1): 131.     CrossRef
  • Causes of hepatic capsular retraction: a pictorial essay
    Gary Xia Vern Tan, Rhian Miranda, Tom Sutherland
    Insights into Imaging.2016; 7(6): 831.     CrossRef
  • Pseudocirrhosis in Gastric Cancer with Diffuse Liver Metastases after a Dramatic Response to Chemotherapy
    Seiichiro Mitani, Shigenori Kadowaki, Hiroya Taniguchi, Hisanori Muto, Kei Muro
    Case Reports in Oncology.2016; 9(1): 106.     CrossRef
  • Pseudocirrhosis: A Case Series and Literature Review
    Abimbola Adike, Nina Karlin, Christine Menias, Elizabeth J. Carey
    Case Reports in Gastroenterology.2016; 10(2): 381.     CrossRef
  • Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective
    Danny Ngo, Jemianne Bautista Jia, Christopher S. Green, Anjalie T. Gulati, Chandana Lall
    Insights into Imaging.2015; 6(6): 665.     CrossRef
  • Liposomes, modified with PTDHIV-1 peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer
    Rui-Jun Ju, Xue-Tao Li, Ji-Feng Shi, Xiu-Ying Li, Meng-Ge Sun, Fan Zeng, Jia Zhou, Lei Liu, Cheng-Xiang Zhang, Wei-Yu Zhao, Wan-Liang Lu
    Biomaterials.2014; 35(26): 7610.     CrossRef
  • 15,909 View
  • 179 Download
  • 26 Web of Science
  • 25 Crossref
Close layer
Original Articles
ERCC1 Can Be a Prognostic Factor in Hilar Cholangiocarcinoma and Extrahepatic Bile Duct Cancer, But Not in Intrahepatic Cholangiocarcinoma
Kyun Woo Park, Eun-Seon Jung, Dong-Gu Kim, Young-Kyung Yoo, Tae-Ho Hong, In Seok Lee, Yoon Ho Koh, Ji-Hoon Kim, Myung Ah Lee
Cancer Res Treat. 2013;45(1):63-69.   Published online March 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.1.63
AbstractAbstract PDFPubReaderePub
PURPOSE
There are three types of bile duct cancer, intrahepatic cholangiocarcinoma (ICC), hilar cholangiocarcinoma (HC), and extrahepatic cholangiocarcinoma (EHC). Despite different clinical presentation, the same protocol has been used in treatment of patients with these cancers. We analyzed clinicopathologic findings and protein expression in order to investigate the difference and the specific prognostic factors among these three types of cancers.
MATERIALS AND METHODS
We conducted a retrospective review of 104 patients diagnosed with bile duct cancer at Seoul St. Mary's Hospital between January 1994 and May 2004. We performed immunohistochemical staining for p53, cyclin D1, thymidine phosphorylase, survivin, and excision repair cross-complementing group 1 (ERCC1).
RESULTS
Of the 104 patients, EHC was most common (44.2%). In pathologic findings, perineural invasion was significantly less common in ICC. Overall survival was similar among the three types of cancer. Lymph node invasion, lymphatic, and venous invasion showed a significant association with survival outcome in ICC, however, the differentiation of histologic grade had prognostic significance in HC and EHC. No difference in protein expression was observed among these types of cancer, however, ERCC1 showed a significant association with survival outcome in HC and EHC, not in ICC.
CONCLUSION
Based on our data, ICC showed different characteristics and prognostic factors, separate from the other two types of bile duct cancer. Conduct of further studies with a large sample size is required in order to confirm these data.

Citations

Citations to this article as recorded by  
  • Systematic Review of Preoperative Prognostic Biomarkers in Perihilar Cholangiocarcinoma
    Rishaan Pawaskar, Kevin Zhang Huang, Helen Pham, Adnan Nagrial, Mark Wong, Siobhan O’Neill, Henry Pleass, Lawrence Yuen, Vincent W. T. Lam, Arthur Richardson, Tony Pang, Christopher B. Nahm
    Cancers.2024; 16(4): 698.     CrossRef
  • Combined Serum ALBUMIN with Neutrophil-to-Lymphocyte Ratio Predicts the Prognosis of Biliary Tract Cancer after Curative Resection
    Tai-Jan Chiu, Yueh-Wei Liu, Chee-Chien Yong, Shih-Min Yin, Cheng-His Yeh, Yen-Yang Chen
    Cancers.2023; 15(22): 5474.     CrossRef
  • Immunotherapy for Cholangiocarcinoma: a 2021 Update
    Nikolaos Charalampakis, Georgios Papageorgiou, Sergios Tsakatikas, Rodanthi Fioretzaki, Christo Kole, Stylianos Kykalos, Maria Tolia, Dimitrios Schizas
    Immunotherapy.2021; 13(13): 1113.     CrossRef
  • Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients
    Andrea Ruzzenente, Matteo Fassan, Simone Conci, Michele Simbolo, Rita T. Lawlor, Corrado Pedrazzani, Paola Capelli, Mirko D’Onofrio, Calogero Iacono, Aldo Scarpa, Alfredo Guglielmi
    Annals of Surgical Oncology.2016; 23(5): 1699.     CrossRef
  • Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib
    Sui Peng, Yanyan Zhang, Hong Peng, Zunfu Ke, Lixia Xu, Tianhong Su, Allan Tsung, Samer Tohme, Hai Huang, Qiuyang Zhang, Riccardo Lencioni, Zhirong Zeng, Baogang Peng, Minhu Chen, Ming Kuang
    Cancer Letters.2016; 373(2): 193.     CrossRef
  • Prognostic Significance of the Histologic Response of Perihilar Cholangiocarcinoma to Preoperative Neoadjuvant Chemoradiation in Liver Explants
    Heidi D. Lehrke, Julie K. Heimbach, Tsung-Teh Wu, Sarah M. Jenkins, Gregory J. Gores, Charles B. Rosen, Taofic Mounajjed
    American Journal of Surgical Pathology.2016; 40(4): 510.     CrossRef
  • Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers
    Muhtashim Mian, Mairéad G McNamara, Mark Doherty, David Hedley, Jennifer J Knox, Stefano Serra
    Journal of Clinical Pathology.2016; 69(8): 695.     CrossRef
  • Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma
    Hong Peng, Qiuyang Zhang, Jiali Li, Ning Zhang, Yunpeng Hua, Lixia Xu, Yubin Deng, Jiaming Lai, Zhenwei Peng, Baogang Peng, Minhu Chen, Sui Peng, Ming Kuang
    Oncotarget.2016; 7(13): 17220.     CrossRef
  • Correlation between metastatic lymph node ratio and prognosis in patients with extrahepatic cholangiocarcinoma
    Jian-Wei Zhang
    World Journal of Gastroenterology.2015; 21(14): 4255.     CrossRef
  • 12,333 View
  • 49 Download
  • 9 Crossref
Close layer
Clinical Significance of Vascular Endothelial Growth Factors (VEGF)-C and -D in Resected Non-Small Cell Lung Cancer
Yoon Ho Ko, Chan-Kwon Jung, Myung-Ah Lee, Jae Ho Byun, Jin Hyoung Kang, Kyo Young Lee, Keon Hyun Jo, Young Pil Wang, Young Seon Hong
Cancer Res Treat. 2008;40(3):133-140.   Published online September 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.3.133
AbstractAbstract PDFPubReaderePub
Purpose

Lymphatic spread of tumor is an important prognostic factor for patients with non-small cell lung carcinoma (NSCLC). Vascular endothelial growth factor-C (VEGF-C) and VEGF-D play important roles in lymphangiogenesis via the VEGF receptor 3 (VEGFR-3). We sought to determine whether VEGF-C, VEGF-D and VEGFR-3 are involved in the clinical outcomes of patients with resected NSCLC.

Materials and Methods

Using immunohistochemical staining, we investigated the protein expressions of VEGF-C, VEGF-D and VEGFR-3 in the tissue array specimens from patients who underwent resection for NSCLC. The immunoreactivity for p53 was also examined. The clinicopathological implications of these molecules were statistically analyzed.

Results

Analysis of a total of 118 specimens showed that VEGF-C, VEGF-D and their co-expression were significantly associated with more advanced regional lymph node metastasis (p=0.019, p=0.044 and p=0.026, respectively, N2 versus N0 and N1). A VEGFR-3 expression had a strong correlation with peritumoral lymphatic invasion (p=0.047). On the multivariate analysis for survival and recurrence, pathologic N2 lymph node metastasis was the only independent prognostic factor, but none of the investigated molecules showed any statistical correlation with recurrence and survival.

Conclusions

The present study revealed that high expressions of VEGF-C and VEGF-D were strongly associated with more advanced regional lymph node metastasis in patients with resected NSCLC.

Citations

Citations to this article as recorded by  
  • Advances in lymphatic metastasis of non-small cell lung cancer
    Xiaofei Zhang, Li Ma, Man Xue, Yanning Sun, Zhaoxia Wang
    Cell Communication and Signaling.2024;[Epub]     CrossRef
  • Prediction of VEGF and EGFR Expression in Peripheral Lung Cancer Based on the Radiomics Model of Spectral CT Enhanced Images
    Linhua Wu, Jian Li, Xiaowei Ruan, Jialiang Ren, Xuejun Ping, Bing Chen
    International Journal of General Medicine.2022; Volume 15: 6725.     CrossRef
  • Lymphangiogenesis in Gastric Cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis
    Hongxia Chen, Runnian Guan, Yupeng Lei, Jianyong Chen, Qi Ge, Xiaoshen Zhang, Ruoxu Dou, Hongyuan Chen, Hao Liu, Xiaolong Qi, Xiaodong Zhou, Changyan Chen
    BMC Cancer.2015;[Epub]     CrossRef
  • Prognostic Impact of Elevation of Vascular Endothelial Growth Factor Family Expression in Patients with Non-small Cell lung Cancer: an Updated Meta-analysis
    Chun-Long Zheng, Chen Qiu, Mei-Xiao Shen, Xiao Qu, Tie-Hong Zhang, Ji-Hong Zhang, Jia-Jun Du
    Asian Pacific Journal of Cancer Prevention.2015; 16(5): 1881.     CrossRef
  • Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer - A Structured Review with Meta-Analysis
    Thomas K. Kilvaer, Erna-Elise Paulsen, Sigurd M. Hald, Tom Wilsgaard, Roy M. Bremnes, Lill-Tove Busund, Tom Donnem, Xin-Yuan Guan
    PLOS ONE.2015; 10(8): e0132481.     CrossRef
  • A Gene Signature Combining the Tissue Expression of Three Angiogenic Factors is a Prognostic Marker in Early-stage Non-small Cell Lung Cancer
    Elena Sanmartín, Rafael Sirera, Marta Usó, Ana Blasco, Sandra Gallach, Santiago Figueroa, Nieves Martínez, Cristina Hernando, Antonio Honguero, Miguel Martorell, Ricardo Guijarro, Rafael Rosell, Eloisa Jantus-Lewintre, Carlos Camps
    Annals of Surgical Oncology.2014; 21(2): 612.     CrossRef
  • VEGF-C in non-small cell lung cancer: Meta-analysis
    Hao Jiang, Wei Shao, Wei Zhao
    Clinica Chimica Acta.2014; 427: 94.     CrossRef
  • High density of peritumoral lymphatic vessels measured by D2-40/podoplanin and LYVE-1 expression in gastric cancer patients: an excellent prognostic indicator or a false friend?
    Julia Rudno-Rudzinska, Wojciech Kielan, Zygmunt Grzebieniak, Piotr Dziegiel, Piotr Donizy, Grzegorz Mazur, Monika Knakiewicz, Ewelina Frejlich, Agnieszka Halon
    Gastric Cancer.2013; 16(4): 513.     CrossRef
  • Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients
    Valsamo K. Anagnostou, Dina G. Tiniakos, Marianthi Fotinou, Apostolos Achimastos, Konstantinos N. Syrigos
    Virchows Archiv.2011; 458(3): 331.     CrossRef
  • Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma
    JUNG YEON KIM, BYUNG-NOE BAE, JI EUN KWON, HYUN-JUNG KIM, KYEONGMEE PARK
    APMIS.2011; 119(7): 449.     CrossRef
  • Supplementation with a-Tocopherol or ß-Carotene Reduces Serum Concentrations of Vascular Endothelial Growth Factor-D, but Not -A or -C, in Male Smokers
    Alison M. Mondul, Helen C. Rager, William Kopp, Jarmo Virtamo, Demetrius Albanes
    The Journal of Nutrition.2011; 141(11): 2030.     CrossRef
  • Expression Analysis of Angiogenesis-Related Genes in Bulgarian Patients with Early-Stage Non-Small Cell Lung Cancer
    Svetlana Nikolova Metodieva, Dragomira Nikolaeva Nikolova, Radostina Vlaeva Cherneva, Ivanka Istalianova Dimova, Danail Borisov Petrov, Draga Ivanova Toncheva
    Tumori Journal.2011; 97(1): 86.     CrossRef
  • 9,868 View
  • 47 Download
  • 12 Crossref
Close layer
Treatment Outcome of Cisplatin-based Concurrent Chemoradiotherapy in the Patients with Locally Advanced Nasopharyngeal Cancer
Tae Hee Kim, Yoon Ho Ko, Myung Ah Lee, Bum-soo Kim, So Ryoung Chung, Ie Ryung Yoo, Chan-Kwon Jung, Yeon-Sil Kim, Min Sik Kim, Dong-Il Sun, Young Seon Hong, Kyung Shik Lee, Jin-Hyoung Kang
Cancer Res Treat. 2008;40(2):62-70.   Published online June 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.2.62
AbstractAbstract PDFPubReaderePub
Purpose

The standard treatment of locally advanced nasopharyngeal cancer is a concurrent chemoradiotherapy (CCRT), and cisplatin has been used as the most popular chemotherapeutic agent. But many different doses and schedules for cisplatin administration such as daily, weekly and 3 week cycles have been proposed. We compared and analyzed the tumor response, the overall survival, the toxicity and the chemotherapy dose intensity in the patients with locally advanced nasopharyngeal cancer who were treated with CCRT.

Materials and Methods

We performed a retrospective study on 55 patients with locally advanced nasopharyngeal cancer, and they were treated with CCRT as a front-line treatment from Jan 1996 to Jun 2007 at Kangnam Saint Mary's Hospital.

Results

The patients had a median age of 53 years (range: 19~75 years). Of the total 55 patients, a 3-week cycle of 100mg cisplatin was administered in 31 patients and 30 mg weekly cisplatin was administered in 24 patients combined with radiotherapy. Twenty one patients had a complete response and four patients had a partial response for a response rate of 71.4% (95% CI: 59.5~83.3) after CCRT and followed by adjuvant chemotherapy. The complete response rates for the 30 mg and 100 mg cisplatin groups were 72.7% (95% CI: 54.9~90.5) and 54.2% (95% CI: 36.7~71.7), respectively (p=0.23). The duration of CCRT in the 100mg cisplatin group was significantly longer than that of the 30mg cisplatin group (11.1±2.9 weeks vs. 9.0±1.2 weeks, p=0.003). The major deviation group, which was defined as prolongation of the radiotherapy duration for more than 2 weeks, had a significantly lower objective response rate than did the non-deviation group (56.3% vs 84.2%, respectively, p=0.002). The major severe toxicities were leucopenia (49.1%), pharyngoesophagitis (49.1%), anorexia (43.6%), nausea (41.8%) and vomiting (40%).

Conclusions

Weekly 30mg cisplatin-based CCRT is a practical, feasible cisplatin schedule for the patients with locally advanced nasopharyngeal cancer in regard to decreasing the interruption of radiation treatment and decreasing the treatment-related acute toxicities.

Citations

Citations to this article as recorded by  
  • A prognostic and predictive model based on deep learning to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma: A retrospective multicenter study
    Jiong-Lin Liang, Yue-Feng Wen, Ying-Ping Huang, Jia Guo, Yun He, Hong-Wei Xing, Ling Guo, Hai-Qiang Mai, Qi Yang
    Radiotherapy and Oncology.2025; 203: 110660.     CrossRef
  • The Effect of Prolonged Duration of Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma
    Yi-Jun Hua, Yan-Feng Ou-Yang, Xiong Zou, Le Xia, Dong-Hua Luo, Ming-Yuan Chen
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Taxane-based Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: Prospective Results from a Non-endemic Cohort
    S. Ghosh-Laskar, A. Pilar, K. Prabhash, A. Joshi, J.P. Agarwal, T. Gupta, A. Budrukkar, V. Murthy, M. Swain, V. Noronha, V.M. Patil, P. Pai, D. Nair, D.A. Chaukar, S. Thiagarajan, G. Pantvaidya, A. Deshmukh, P. Chaturvedi, S. Nair, A. D‘Cruz
    Clinical Oncology.2019; 31(12): 850.     CrossRef
  • Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study
    Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie
    Tumor Biology.2016; 37(4): 4429.     CrossRef
  • Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: a meta-analysis based on randomized controlled trials
    Cheng-run Du, Hong-mei Ying, Fang-fang Kong, Rui-ping Zhai, Chao-su Hu
    Radiation Oncology.2015;[Epub]     CrossRef
  • Concurrent Chemotherapy for T4 Classification Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy
    Cai-neng Cao, Jing-wei Luo, Li Gao, Jun-lin Yi, Xiao-dong Huang, Kai Wang, Shi-ping Zhang, Yuan Qu, Su-yan Li, Jian-ping Xiao, Zhong Zhang, Guo-zhen Xu, Riccardo Dolcetti
    PLOS ONE.2015; 10(3): e0119101.     CrossRef
  • Controversies in the systemic treatment of Nasopharyngeal carcinoma
    Herbert H. Loong, Anthony T.C. Chan
    Oral Oncology.2014; 50(9): 785.     CrossRef
  • Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma
    Junlin Yi, Xiaodong Huang, Li Gao, Jingwei Luo, Shiping Zhang, Kai Wang, Yuan Qu, Jianping Xiao, Guozhen Xu
    Radiation Oncology.2014;[Epub]     CrossRef
  • Factors Predict Prolonged Wait Time and Longer Duration of Radiotherapy in Patients with Nasopharyngeal Carcinoma: A Multilevel Analysis
    Po-Chun Chen, Ching-Chieh Yang, Cheng-Jung Wu, Wen-Shan Liu, Wei-Lun Huang, Ching-Chih Lee, Bart O. Williams
    PLoS ONE.2014; 9(10): e109930.     CrossRef
  • Pretreatment Epstein-Barr Virus DNA Load and Cumulative Cisplatin Dose Intensity Affect Long-Term Outcome of Nasopharyngeal Carcinoma Treated with Concurrent Chemotherapy: Experience of an Institute in an Endemic Area
    Weihong Wei, Zeli Huang, Shaoen Li, Hemei Chen, Guoyi Zhang, Shuxia Li, Weihan Hu, Tao Xu
    Oncology Research and Treatment.2014; 37(3): 88.     CrossRef
  • Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial
    Qiu-Yan Chen, Yue-Feng Wen, Ling Guo, Huai Liu, Pei-Yu Huang, Hao-Yuan Mo, Ning-Wei Li, Yan-Qun Xiang, Dong-Hua Luo, Fang Qiu, Rui Sun, Man-Quan Deng, Ming-Yuan Chen, Yi-Jun Hua, Xiang Guo, Ka-Jia Cao, Ming-Huang Hong, Chao-Nan Qian, Hai-Qiang Mai
    JNCI: Journal of the National Cancer Institute.2011; 103(23): 1761.     CrossRef
  • Radiation Therapy Combined with (or without) Cisplatin-based Chemotherapy for Patients with Nasopharyngeal Cancer: 15-years Experience of a Single Institution in Korea
    Yeon-Sil Kim, Bum-Soo Kim, So-Lyoung Jung, Yeon-Soo Lee, Min-Sik Kim, Dong-Il Sun, Eun-Jung Yoo, Seong-Kwon Mun, Sei-Chul Yoon, Su-Mi Chung, Hoon-Kyo Kim, Seung-Ho Jo, Jin-Hyoung Kang
    Cancer Research and Treatment.2008; 40(4): 155.     CrossRef
  • 12,405 View
  • 70 Download
  • 12 Crossref
Close layer
Clinical Characteristics of Primary Peritoneal Carcinoma
Sang Young Roh, Sook Hee Hong, Yoon Ho Ko, Tae Hee Kim, Myung Ah Lee, Byoung Yong Shim, Jae Ho Byun, In Sook Woo, Jin Hyoung Kang, Young Seon Hong, Kyung Shik Lee
Cancer Res Treat. 2007;39(2):65-68.   Published online June 30, 2007
DOI: https://doi.org/10.4143/crt.2007.39.2.65
AbstractAbstract PDFPubReaderePub
Purpose

The goal of this study was to determine the clinical and therapeutic characteristics of women with a primary peritoneal carcinoma (PPC).

Materials and Methods

A retrospective clinical study was conducted to evaluate 22 women diagnosed with a PPC from 1993 to 2007 at the Hospitals of The Catholic University of Korea. Diagnoses were based on the Gynecologic Oncology Group criteria and clinical data. We collected patient clinicopathological data including age, presenting symptoms, pretreatment CA-125 values (U/ml), clinical stage (based on the FIGO stage), performance status (using the Eastern Cooperative Oncology Group scale), whether cytoreductive surgery was optimal or not, types of chemotherapy and response to treatment. We evaluated the clinical characteristics and response to treatment, time to treatment failure and overall survival.

Results

The median overall survival of all patients was 23.1 months. The estimated 3-year survival rate was 29% (SE, 13%). The response rate to first-line platinum-based chemotherapy was 79% and the median time to treatment failure was 9.9 months (95% confidence interval, 1.38~18.4 months). By univariate and multivariate analysis, performance status was the only significant factor associated with overall survival (p<0.05).

Conclusion

We evaluated the clinical characteristics and treatment response of patients with a primary peritoneal carcinoma. Our results showed that it is possible to achieve long-term survival in patients with PPC. A further clinical study is to need to establish clinical characteristics and treatment outcomes.

Citations

Citations to this article as recorded by  
  • Incidentally Diagnosed Low-Grade Primary Peritoneal Serous Carcinoma Within the Umbilical Hernia Sac in a Male: A Report of an Extremely Rare Case and Review of the Literature
    Samer Ganam, Ayesha Khan, Nicole Riddle, Joseph A Sujka, Christopher G DuCoin
    Cureus.2024;[Epub]     CrossRef
  • Primary peritoneal serous carcinoma – A rare case report
    Pradnya Neelakanta Reddy, Eugene J S D'Souza, Avinash Anand
    IP Journal of Diagnostic Pathology and Oncology.2024; 9(4): 244.     CrossRef
  • Primary peritoneal high-grade serous carcinoma in a man: A case report
    Abdelali Guellil, Rachid Jabi, Mohamed Yassine Mabrouk, Laila Bouzayan, Abdelali Merhoum, Gérald Del Gallo, Claire Godart, Mohammed Bouziane
    Annals of Medicine and Surgery.2022; 77: 103605.     CrossRef
  • Primary Peritoneal Carcinoma: A Rare Malignancy Presenting a Diagnostic Challenge
    Mariam Shabbir, Sonu Sahni, Meena Ahluwalia, Raji Ayinla
    Cureus.2022;[Epub]     CrossRef
  • A case of interstitial pneumonia associated with systemic sclerosis and primary peritoneal serous carcinoma successfully treated with cyclophosphamide
    Shunichi Kawamura, Toshio Kubo, Kenji Takada, Ryota Sunami, Sachi Okawa, Yoshitaka Iwamoto, Atsuko Hirabae, Akihiko Taniguchi, Yoshinobu Maeda, Katsuyuki Kiura, Masahiro Tabata
    International Cancer Conference Journal.2021; 10(3): 197.     CrossRef
  • Primary peritoneal mucinous cystadenocarcinoma mimicking possible recurrent ovarian mucinous cystadenoma: coincidental pathology or a spectrum of disease?
    Claire Filippini, Sarah Smyth, Hooman Soleymani Majd, Catherine Johnson
    BMJ Case Reports.2021; 14(7): e242478.     CrossRef
  • Imaging features of primary peritoneal serous carcinoma: A case report
    Ji Soo Oh, Beum Jin Kim, Myoung Jin Ju, Eun Ae Yoo
    Radiology Case Reports.2020; 15(7): 978.     CrossRef
  • Unexpected primary fallopian tube carcinoma during gynecological operations: Clinicopathological and prognostic factors analyses of 67 cases
    Mingming Sun, Lingjie Bao, Haoran Shen, Min Ji, Liangqing Yao, Xiaofang Yi, Wei Jiang
    Taiwanese Journal of Obstetrics and Gynecology.2019; 58(5): 626.     CrossRef
  • Complications of Acute Pancreatitis Misdiagnosed as Primary Serous Papillary Carcinoma
    Jin Wook Lee, Eun Taek Park
    The Korean Journal of Pancreas and Biliary Tract.2018; 23(2): 54.     CrossRef
  • Inguinal Lymph Node Metastasis of a Primary Serous Papillary Carcinoma of the Peritoneum One Year after CRS and HIPEC
    Shadi Katou, Mathilde Feist, Wieland Raue, Johann Pratschke, Beate Rau, Andreas Brandl
    Visceral Medicine.2018; 34(4): 307.     CrossRef
  • Diagnostic and prognostic value of HE4 in female patients with primary peritoneal carcinoma
    Dong Mi, Yuexiang Zhang
    The International Journal of Biological Markers.2018; 33(4): 395.     CrossRef
  • Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review
    Jingping Yuan, Liang He, Bing Han, Yan Li
    World Journal of Surgical Oncology.2017;[Epub]     CrossRef
  • An unusual cancer involving the rectum: two cases of localized primary peritoneal carcinoma mimicking rectal carcinoma
    Jinnie S. Y. Pang, Liying Yang, Ghee Kheng Chew, Min Hoe Chew
    International Journal of Colorectal Disease.2016; 31(3): 717.     CrossRef
  • Primary peritoneal serous carcinoma, an extremely rare malignancy: A case report and review of the literature
    WOO-SUNG YUN, JUNG-MIN BAE
    Oncology Letters.2016; 11(6): 4063.     CrossRef
  • Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms
    Lauren Patterson Cobb, Stephanie Gaillard, Yihong Wang, Ie-Ming Shih, Angeles Alvarez Secord
    Gynecologic Oncology Research and Practice.2015;[Epub]     CrossRef
  • Amylase-Producing Primary Peritoneal Carcinoma
    Ji-Woon Lee, Sang-Gon Park
    The Korean Journal of Medicine.2015; 89(3): 358.     CrossRef
  • Solitary primary peritoneal carcinoma arising from the omentum
    Yi-Jou Tai, Ming-Chieh Lin, Chin-Jui Wu, Chi-An Chen, Wen-Fang Cheng
    Taiwanese Journal of Obstetrics and Gynecology.2014; 53(2): 256.     CrossRef
  • Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report
    Skyler B. Johnson, Joann I. Prisciandaro, Jessica Zhou, Scott W. Hadley, R. Kevin Reynolds, Shruti Jolly
    Journal of Applied Clinical Medical Physics.2014; 15(1): 202.     CrossRef
  • Embryonic natural orifice transumbilical endoscopic surgery (E-NOTES) for adnexal tumors
    Myong Cheol Lim, Tae-Joong Kim, Sokbom Kang, Duk-Soo Bae, Sang-Yoon Park, Sang-Soo Seo
    Surgical Endoscopy.2009; 23(11): 2445.     CrossRef
  • 10,374 View
  • 92 Download
  • 19 Crossref
Close layer
Autologous Stem Cell Transplantation using a Modified TAM Conditioning Regimen for Clinically Aggressive Non-Hodgkin's Lymphoma
Sook Hee Hong, Young Seon Hong, In Sook Woo, Yoon Ho Koh, Sang Young Rho, Ji Yean Peak, Myung Ah Lee, Byoung Yong Shim, Jae Ho Byun, Ji Chan Park, Jong Wook Lee, Woo Sung Min, Chun Choo Kim
Cancer Res Treat. 2007;39(2):54-60.   Published online June 30, 2007
DOI: https://doi.org/10.4143/crt.2007.39.2.54
AbstractAbstract PDFPubReaderePub
Purpose

High-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) have been used for the treatment of clinically aggressive non-Hodgkin's lymphoma (NHL). However, the superiority of specific conditioning regimens has not yet been established. The present study evaluated the efficacy and toxicity of a conditioning regimen involving fractionated total body irradiation (TBI), and the use of Ara-C and melphalan (TAM) for clinically aggressive NHL.

Materials and Methods

Between March 2002 and December 2004, 31 patients with aggressive NHL received fractionated TBI with a dose of 12 Gy over 3 days, and were administered 9 g/m2 Ara-C and 100 mg/m2 melphalan followed by autologous peripheral blood stem Cell Transplantation at the Catholic Hematopoietic Stem cell transplantation Center Korea. Patients that responded to first line chemotherapy and achieved complete remission (CR), or were in a first sensitive relapse were defined as having less advanced disease, while the other patients were defined as having more advanced disease.

Results

Objective responses were obtained in 24 of 31 patients (77.4%), comprising complete remission in 19 patients (61.3%) and partial remission in 5 (16.1%) patients. The median follow-up time was 28 months (range 1~62 months). At 3 years, the overall survival and event-free survival (EFS) rates were 62.3% and 47.3%, respectively. Patients with less advanced disease and more advanced disease showed 3-year EFS rates of 73.3% and 22.5 %, respectively (p=0.006). Early (within the first 100 days) treatment-related mortality occurred in 3 (9.7%) patients. Of the 31 total patients, 15 (48.4%) developed grade 3 mucositis, 22 (70.9%) developed neutropenic fever, and two (6.5%) developed interstitial pneumonia syndrome>grade 3.

Conclusion

The modified TAM conditioning regimen and ASCT appear to be a feasible treatment regimen for clinically aggressive NHL, particularly for patients with less advanced disease.

Citations

Citations to this article as recorded by  
  • Comparison of regional arterial chemotherapy and systemic intravenous chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis
    Chengqing Li, Wenyi Guo, Shihong Chen, Jianwei Xu, Feng Li, Lei Wang
    Journal of Pancreatology.2022; 5(2): 49.     CrossRef
  • 9,705 View
  • 55 Download
  • 1 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP